Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment

被引:25
作者
Buerger, K
Teipel, SJ
Zinkowski, R
Sunderland, T
Andreasen, N
Blennow, K
Ewers, M
DeBernardis, J
Shen, Y
Kerkman, D
Du, YS
Hampel, H
机构
[1] Univ Munich, Dementia Res Sect, D-80336 Munich, Germany
[2] Univ Munich, Memory Clin, Alzheimer Mem Ctr, D-80336 Munich, Germany
[3] Univ Munich, Dept Psychiat, Geriatr Psychiat Branch, D-80336 Munich, Germany
[4] Appl NeuroSolut Inc, Vernon Hills, IL 60061 USA
[5] NIMH, NIH, Geriatr Psychiat Branch 10 3D41, Bethesda, MD 20892 USA
[6] Huddinge Univ Hosp, Karolinska Inst, Div Geriatr Med, Neurotec, S-14186 Huddinge, Sweden
[7] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Neurosci, Unit Neurochem, Molndal, Sweden
[8] Sun Hlth Res Inst, Haldeman Lab Mol & Cellular Neurobiol, Sun City, AZ 85351 USA
[9] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA
关键词
Alzheimer's disease; mild cognitive impairment; apolipoprotein E; risk factor; phosphorylated tau protein; cerebrospinal fluid;
D O I
10.1016/j.neulet.2005.08.030
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We investigated the correlation between the apolipoprotein E epsilon 4 allele (apoE epsilon 4) carrier status, a major risk factor of Alzheimer's disease (AD), and levels of tau protein phosphorylated at threonine 231 (P-tau(231P)) in cerebrospinal fluid (CSF) in predementia and clinical stages of AD and healthy controls (HC). Thirty-one subjects with mild cognitive impairment (MCI) who had converted to AD during follow-up were included, as well as 71 AD patients, and 29 HC subjects. In MCI, but not in AD and HC, CSF P-tau(231P) levels were significantly higher in apoE epsilon 4 carriers compared to non-carriers (p < 0.001). Controlling for disease duration, the apoE epsilon 4 effect on P-tau(231p) remained significant. Our study indicates that the apoE epsilon 4 carrier status should be considered when CSF P-tau(231P) is evaluated as biomarker candidate of AD in MCI subjects. (C) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:48 / 50
页数:3
相关论文
共 13 条
[1]   CSF phosphorylated tau protein and mild cognitive impairment: a prospective study [J].
Arai, H ;
Ishiguro, K ;
Ohno, H ;
Moriyama, M ;
Itoh, N ;
Okamura, N ;
Matsui, T ;
Morikawa, Y ;
Horikawa, E ;
Kohno, H ;
Sasaki, H ;
Imahori, K .
EXPERIMENTAL NEUROLOGY, 2000, 166 (01) :201-203
[2]   CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects [J].
Buerger, K ;
Teipel, SJ ;
Zinkowski, R ;
Blennow, K ;
Arai, H ;
Engel, R ;
Hofmann-Kiefer, K ;
McCulloch, C ;
Ptok, U ;
Heun, R ;
Andreasen, N ;
DeBernardis, J ;
Kerkman, D ;
Moeller, HJ ;
Davies, P ;
Hampel, H .
NEUROLOGY, 2002, 59 (04) :627-629
[3]   Biological markers for therapeutic trials in Alzheimer's disease - Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease [J].
Frank, RA ;
Galasko, D ;
Hampel, H ;
Hardy, J ;
de Leon, MJ ;
Mehta, PD ;
Rogers, J ;
Siemers, E ;
Trojanowski, JQ .
NEUROBIOLOGY OF AGING, 2003, 24 (04) :521-536
[4]   Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment [J].
Hampel, H ;
Teipel, SJ ;
Fuchsberger, T ;
Andreasen, N ;
Wiltfang, J ;
Otto, M ;
Shen, Y ;
Dodel, R ;
Du, Y ;
Farlow, M ;
Möller, HJ ;
Blennow, K ;
Buerger, K .
MOLECULAR PSYCHIATRY, 2004, 9 (07) :705-710
[5]   Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 [J].
Hampel, H ;
Buerger, K ;
Kohnken, R ;
Teipel, SJ ;
Zinkowski, R ;
Moeller, HJ ;
Rapoport, SI ;
Davies, P .
ANNALS OF NEUROLOGY, 2001, 49 (04) :545-546
[6]   Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease [J].
Itoh, N ;
Arai, H ;
Urakami, K ;
Ishiguro, K ;
Ohno, H ;
Hampel, H ;
Buerger, K ;
Wiltfang, J ;
Otto, M ;
Kretzschmar, H ;
Moeller, HJ ;
Imagawa, M ;
Kohno, H ;
Nakashima, K ;
Kuzuhara, S ;
Sasaki, H ;
Imahori, K .
ANNALS OF NEUROLOGY, 2001, 50 (02) :150-156
[7]   Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients [J].
Kohnken, R ;
Buerger, K ;
Zinkowski, R ;
Miller, C ;
Kerkman, D ;
DeBernardis, J ;
Shen, JF ;
Möller, HJ ;
Davies, P ;
Hampel, H .
NEUROSCIENCE LETTERS, 2000, 287 (03) :187-190
[8]   APOLIPOPROTEIN-E STATUS AS A PREDICTOR OF THE DEVELOPMENT OF ALZHEIMERS-DISEASE IN MEMORY-IMPAIRED INDIVIDUALS [J].
PETERSEN, RC ;
SMITH, GE ;
IVNIK, RJ ;
TANGALOS, EG ;
SCHAID, DJ ;
THIBODEAU, SN ;
KOKMEN, E ;
WARING, SC ;
KURLAND, LT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (16) :1274-1278
[9]   Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E [J].
Reiman, EM ;
Caselli, RJ ;
Yun, LS ;
Chen, KW ;
Bandy, D ;
Minoshima, S ;
Thibodeau, SN ;
Osborne, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) :752-758
[10]   Both total and phosphorylated tau are increased in Alzheimer's disease [J].
Sjögren, M ;
Davidsson, P ;
Tullberg, M ;
Minthon, L ;
Wallin, A ;
Wikkelso, C ;
Granerus, AK ;
Vanderstichele, H ;
Vanmechelen, E ;
Blennow, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 70 (05) :624-630